Login to Your Account

Aesrx Seeks to Solve Sickle Cell Disease Puzzle

By Marie Powers
Staff Writer

Monday, September 9, 2013

Five years after its launch, virtual biotech Aesrx LLC has advanced a small molecule anti-sickling agent into a Phase II trial in patients with sickle cell disease (SCD) – and done so without a venture capital round. If the compound proves its mettle, the company could become the first to market a treatment that directly blocks cell sickling rather than seeking simply to reduce the frequency of sickle cell crises.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription